Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
Refractory B-cell Acute Lymphoblastic Leukemia|Relapsed B-cell Acute Lymphoblastic Leukemia
BIOLOGICAL: UCART19
Incidence and Severity of Adverse Events, Adverse events assessed according to NCI-CTCAE v5.0 criteria, From inclusion to Month 12
Molecular Remission Rate, Proportion of patients in whom a molecular Complete Remission (CR) or a Complete Remission with incomplete blood recovery (CRi) is observed (i.e. a CR or CRi combined to a Minimal residual disease \<10-4)., At Day 28 after the first UCART19 infusion
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).